Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director · Chief Executive Officer | March 16, 2026 | March 16, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director · Chief Executive Officer | January 18, 2023 | January 20, 2023 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 95,147 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 95,147 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Joint Account with Spouse | 128,887 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 128,887 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
HERON THERAPEUTICS, INC. /DE/
Report date January 18, 2023 · Filed January 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2033-01-18 | Direct | 850,000 |
Reported balance
After 2023-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-18 · Grant · Acquired 850,000 · Balance 850,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.
Kiniksa Pharmaceuticals International, plc
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 12,745 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 2,600 · Balance 12,745 F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2023 Filed Jan 20, 2023 22:10 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 850,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001209191-23-004303 · doc4.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 16,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003563 · doc4.xml · derivative · entry 6 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,807 Underlying: Common Stock · 16,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003563 · doc4.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,521 Underlying: Common Stock · 3,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 5,219 | $3.17 | $16,544.23 |
DisclosureSEC source: 0001209191-23-003563 · doc4.xml · nonDerivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,989 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 16,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-003563 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-003563 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 21,959 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-22-011878 · form4-12012022_091249.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 21,959 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 21,959 | $16.15 | $354,637.85 |
DisclosureSEC source: 0001415889-22-011878 · form4-12012022_091249.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.09 to $16.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Class A Common Shares sold at each price. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 21,959 | $1.59 | $34,914.81 |
DisclosureSEC source: 0001415889-22-011878 · form4-12012022_091249.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Jan 17, 2023 22:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,655 | $3.27 | $5,415.99 |
DisclosureSEC source: 0001209191-23-003563 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,441 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 16,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053835 · doc4.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,929 Underlying: Common Stock · 16,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053835 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 5,219 | $3.76 | $19,623.44 |
DisclosureSEC source: 0001209191-22-053835 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,786 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 16,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053835 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:38 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053835 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 16,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042262 · doc4.xml · derivative · entry 6 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,051 Underlying: Common Stock · 16,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042262 · doc4.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,812 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 5,219 | $3.01 | $15,709.19 |
DisclosureSEC source: 0001209191-22-042262 · doc4.xml · nonDerivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,237 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 16,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042262 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042262 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007108 · form4-06302022_010649.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 30,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001415889-22-007108 · form4-06302022_010649.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022. Read SEC document |
| April 29, 2022 Filed Jul 15, 2022 20:57 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,504 | $3.84 | $5,778.37 |
DisclosureSEC source: 0001209191-22-042262 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,688 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 16,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024522 · doc4.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,173 Underlying: Common Stock · 16,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024522 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,458 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 5,219 | $6.07 | $31,679.33 |
DisclosureSEC source: 0001209191-22-024522 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,184 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 16,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024522 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 21:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024522 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:08 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 16,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003362 · doc4.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,295 Underlying: Common Stock · 16,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:08 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003362 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,104 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:08 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 5,219 | $8.30 | $43,317.70 |
DisclosureSEC source: 0001209191-22-003362 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,635 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:08 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 16,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003362 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2022 Filed Jan 14, 2022 22:08 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003362 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:25 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 195,417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060551 · doc4.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,417 Underlying: Common Stock · 195,417 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:25 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 390,834 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001209191-21-060551 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,834 Underlying: Common Stock · 390,834 shares Expires 2031-10-13 F4 · derivative.exercise_date: The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:25 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060551 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:25 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 963 | $10.55 | $10,159.65 |
DisclosureSEC source: 0001209191-21-060551 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,086 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 20:25 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060551 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046790 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,396 Underlying: Common Stock · 3,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 963 | $13.48 | $12,981.24 |
DisclosureSEC source: 0001209191-21-046790 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,403 F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046790 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,237 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001179110-21-007183 · edgar.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,237 Underlying: Class A Common Shares · 33,237 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021. Read SEC document |
| April 30, 2021 Filed Jul 15, 2021 20:50 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,529 | $13.90 | $21,249.28 |
DisclosureSEC source: 0001209191-21-046790 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,721 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026844 · doc4.xml · derivative · entry 6 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,041 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F5 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 963 | $16.66 | $16,043.58 |
DisclosureSEC source: 0001209191-21-026844 · doc4.xml · nonDerivative · entry 5 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,192 F4 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock units to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026844 · doc4.xml · nonDerivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003804 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,687 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020). Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 963 | $18.16 | $17,488.08 |
DisclosureSEC source: 0001209191-21-003804 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,909 F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-003804 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 58,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054907 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,333 Underlying: Common Stock · 58,333 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.